Impact of dietary modification of advanced glycation end products (AGEs) on the hormonal and metabolic profile of women with polycystic ovary syndrome (PCOS)

Hormones

Volumn 13, Issue 1, 2014, Pages 65-73

  Tantalaki, Evangelia ^a   Piperi, Christina ^a   Livadas, Sarantis ^a   Kollias, Anastasios ^a   Adamopoulos, Christos ^a   Koulouri, Aikaterini ^a   Christakou, Charikleia ^a   Diamanti Kandarakis, Evanthia ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Dietary advanced glycation end products (AGEs); Insulin resistance; Oxidative stress; Polycystic ovary syndrome; Testosterone

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ENDOCRINE DISRUPTOR; INSULIN; TESTOSTERONE;

ADULT; ANOVULATION; ARTICLE; BODY MASS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET; FEMALE; FOOD INTAKE; HORMONAL REGULATION; HORMONE METABOLISM; HUMAN; HUMIDITY; HYPERANDROGENISM; IMMUNOREACTIVITY; INSULIN BLOOD LEVEL; KOLMOGOROV SMIRNOV TEST; LIFESTYLE; MENSTRUAL CYCLE; METABOLIC REGULATION; OVARY POLYCYSTIC DISEASE; OXIDATIVE STRESS; PROTEIN TRANSPORT; TESTOSTERONE BLOOD LEVEL; YOUNG ADULT; ADOLESCENT; BLOOD; DIET THERAPY; INSULIN RESISTANCE; LOW CALORY DIET; PHYSIOLOGY;

ADOLESCENT; ADULT; DIET, REDUCING; FEMALE; GLYCOSYLATION END PRODUCTS, ADVANCED; HUMANS; INSULIN; INSULIN RESISTANCE; OXIDATIVE STRESS; POLYCYSTIC OVARY SYNDROME; TESTOSTERONE; YOUNG ADULT;

EID: 84899639034     PISSN: 11093099     EISSN: None     Source Type: Journal    
DOI: 10.1007/bf03401321     Document Type: Article

References (45)

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, et al, 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. J Clin Endocrinol Metab 84: 4006-4011.
2. Poretsky L, Cataldo NA, Rosenwaks Z, Giudice LC, 1999 The insulin-related ovarian regulatory system in health and disease. Endocr Rev 20: 535-582.
3. Brownlee M, Vlassara H, Cerami A, 1984 Nonenzymatic glycosylation and the pathogenesis of diabetic complications. Ann Intern Med 101: 527-537.
4. Vlassara H, Cai W, Crandall J, et al, 2002 Inflammatory mediators are induced by dietary glycotoxins, a major risk factor for diabetic angiopathy. Proc Natl Acad Sci USA 99: 15596-15601.
5. Uribarri J, Cai W, Sandu O, Peppa M, Goldberg T, Vlassara H, 2005 Diet-derived advanced glycation end products are major contributors to the body's AGE pool and induce inflammation in healthy subjects. Ann NY Acad Sci 1043: 461-466.
6. Ahmed N, 2005 Advanced glycation end products-role in pathology of diabetic complications. Diabetes Res Clin Pract 67: 3-21.
7. Ahmed N, Thornalley PJ, 2003 Quantitative screening of protein biomarkers of early glycation, advanced glycation, oxidation and nitrosation in cellular and extracellular proteins by tandem mass spectrometry multiple reaction monitoring. Biochem Soc Trans 31: 1417-1422.
8. Diamanti-Kandarakis E, Katsikis I, Piperi C, et al, 2008 Increased serum advanced glycation end-products is a distinct finding in lean women with polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 69: 634-641.
9. Diamanti-Kandarakis E, Piperi C, Kalofoutis A, Creatsas G, 2005 Increased levels of serum advanced glycation end-products in women with polycystic ovary syndrome. Clin Endocrinol (Oxf) 62: 37-43.
10. Diamanti-Kandarakis E, Piouka A, Livadas S, et al, 2009 Anti-mullerian hormone is associated with advanced glycosylated end products in lean women with polycystic ovary syndrome. Eur J Endocrinol 160: 847-853.
11. Diamanti-Kandarakis E, Piperi C, Patsouris E, 2007 Immunohistochemical localization of advanced glycation end-products (AGEs) and their receptor (RAGE) in polycystic and normal ovaries. Histochem Cell Biol 127: 581-589.
12. Ames JM, 2008 Determination of N epsilon-(carboxymethyl) lysine in foods and related systems. Ann NY Acad Sci 1126: 20-24.
13. Uribarri J, Cai W, Peppa, M, et al, 2007 Circulating glycotoxins and dietary advanced glycation endproducts: two links to inflammatory response, oxidative stress, and aging. J Gerontol A Biol Sci Med Sci 62: 427-433.
14. Uribarri J, Stirban A, Sander D, et al, 2007 Single oral challenge by advanced glycation end products acutely impairs endothelial function in diabetic and nondiabetic subjects. Diabetes Care 30: 2579-2582.
15. Koschinsky T, He CJ, Mitsuhashi T, et al, 1997 Orally absorbed reactive glycation products (glycotoxins): an environmental risk factor in diabetic nephropathy. Proc Natl Acad Sci USA 94: 6474-6479.
16. Sebekova K, Krajcoviova-Kudlackova M, Schinzel R, Faist V, Klvanová J, Heidland A, 2001 Plasma levels of advanced glycation end products in healthy, long-term vegetarians and subjects on a western mixed diet. Eur J Nutr 40: 275-281.
17. Uribarri J, Peppa M, Cai, W, et al, 2003 Dietary glycotoxins correlate with circulating advanced glycation end product levels in renal failure patients. Am J Kidney Dis 42: 532-538.
18. Negrean M, Stirban A, Stratmann, B, et al, 2007 Effects of low-and high-advanced glycation endproduct meals on macro-and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. Am J Clin Nutr 85: 1236-1243.
19. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al, 2009 Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev 30: 293-342.
20. Diamanti-Kandarakis E, Piperi C, Alexandraki K, et al, 2006 Short-term effect of orlistat on dietary glycotoxins in healthy women and women with polycystic ovary syndrome. Metabolism 55: 494-500.
21. Diamanti-Kandarakis E, Piperi C, Alexandraki KI, et al, 2009 The acute effect of Orlistat on dietary glycotoxins in diabetics and healthy women. Minerva Endocrinol 34: 97-104.
22. Diamanti-Kandarakis E, Piperi C, Korkolopoulou P, et al, 2007 Accumulation of dietary glycotoxins in the reproductive system of normal female rats. J Mol Med (Berl) 85: 1413-1420.
23. Zawadzki JK, Dunaif A 1990 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine F, Merriam GR, eds. Polycystic ovary syndrome. Blackwell Scientific Publications, Boston; pp, 377-384.
24. Mitsuhashi T, Vlassara H, Founds HW, Li YM, 1997 Standardizing the immunological measurement of advanced glycation endproducts using normal human serum. J Immunol Methods 207: 79-88.
25. Sheetz MJ, King GL, 2002 Molecular understanding of hyperglycemia's adverse effects for diabetic complications. JAMA 288: 2579-2588.
26. Lin L, Park S, Lakatta EG, 2009 RAGE signaling in inflammation and arterial aging. Front Biosci 14: 1403-1413.
27. Makita Z, Radoff S, Rayfield EJ, et al, 1991 Advanced glycosylation end products in patients with diabetic nephropathy. N Engl J Med 325: 836-842.
28. Ono Y, Aoki S, Ohnishi K, et al, 1998 Increased serum levels of advanced glycation end products in NIDDM patients with diabetic complications. Diabetes Care 21: 1027.
29. Busch M, Franke S, Ruster C, Wolf G, 2010 Advanced glycation end-products and the kidney. Eur J Clin Invest 40: 742-755.
30. Forster A, Kuhne Y, Henle T, 2005 Studies on absorption and elimination of dietary maillard reaction products. Ann NY Acad Sci 1043: 474-481.
31. Geissler S, Hellwig M, Zwarg M, Markwardt F, Henle T, Brandsch M, 2010 Transport of the advanced glycation end products alanylpyrraline and pyrralylalanine by the human proton-coupled peptide transporter hPEPT1. J Agric Food Chem 58: 2543-2547.
32. Hofmann SM, Dong HJ, Li Z, et al, 2002 Improved insulin sensitivity is associated with restricted intake of dietary glycoxidation products in the db/db mouse. Diabetes 51: 2082-2089.
33. Peppa M, Brem H, Ehrlich P, et al, 2003 Adverse effects of dietary glycotoxins on wound healing in genetically diabetic mice. Diabetes 52: 2805-2813.
34. Peppa M, Uribarri J, Vlassara H, 2004 The role of advanced glycation end products in the development of atherosclerosis. Curr Diab Rep 4: 31-36.
35. Stirban A, Negrean M, Gotting C, et al, 2008 Dietary advanced glycation endproducts and oxidative stress: in vivo effects on endothelial function and adipokines. Ann N Y Acad Sci 1126: 276-279.
36. Altieri P, Cavazza C, Pasqui F, Morselli AM, Gambieri A, Pasquali R, 2013 Dietary habits and their relationship with hormones and metabolism in overweight and obese women with polycystic ovary syndrome. Clin Endocr 78: 52-59.
37. Cassese A, Esposito I, Fiory F, et al, 2008 In skeletal muscle advanced glycation end products (AGEs) inhibit insulin action and induce the formation of multimolecular complexes including the receptor for AGEs. J Biol Chem 283: 36088-36099.
38. Lo MC, Lu CI, Chen MH, et al, 2010 Glycoxidative stress-induced mitophagy modulates mitochondrial fates. Ann N Y Acad Sci 1201: 1-7.
39. Otani H 2011 Oxidative stress as pathogenesis of cardiovascular risk associated with metabolic syndrome. Antioxid Redox Signal 15: 1911-1926.
40. Sabuncu T, Vural H, Harma M, Harma M, 2001 Oxidative stress in polycystic ovary syndrome and its contribution to the risk of cardiovascular disease. Clin Biochem 34: 407-413.
41. González F, Rote NS, Minium J, Kirwan JP, 2006 Reactive oxygen species-induced oxidative stress in the development of insulin resistance and hyperandrogenism in polycystic ovary syndrome. J Clin Endocrinol Metab 91: 336-340.
42. Uribarri J, Woodruff S, Goodman S, et al, 2010 Advanced glycation end products in foods and a practical guide to their reduction in the diet. J Am Diet Assoc 110: 911-916.
43. Pouillart P, Mauprivez H, Ait-Ameur L, et al, 2008 Strategy for the study of the health impact of dietary Maillard products in clinical studies: the example of the ICARE clinical study on healthy adults. Ann N Y Acad Sci 1126: 173-176.
44. Senn SS 2002, Cross-over Trials in Clinical Research. John Wiley and Son, Chichester 2002.
45. Pignone MP, Ammerman A, Fernandez L, et al, 2003 Counseling to promote a healthy diet in adults: a summary of the evidence for the U.S. Preventive Services Task Force. Am J Prev Med 24: 75-92.